Validate a diagnostic and prognostic test that predicts the risk of developing esophageal cancer, the fastest-growing cancer by incidence in western countries. The test employs a “spatial systems biology approach” to pathological testing that simultaneously evaluates multiple cells and processes in a single biopsy. The current process is largely manual and subjective. Cernostics is developing this technology in collaboration with Geisinger Health System, University of Pennsylvania, University of Pittsburgh, and the Academic Medical Center in Amsterdam, The Netherlands.